Drugs / NKG2D CAR-NK cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07021534 | Jun 2025 → Dec 2026 expected | — | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07577986 | May 2026 → May 2027 expected | HIV infectious disease | First Affiliated Hospital of Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04324996 | Feb 2020 → Feb 2022 | COVID-19 | Chongqing Public Health Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG2D CAR-NK cells | “During this period, participants will receive two cycles of intravenous infusion of allogeneic NKG2D CAR-NK cells (each cycle consisting of two consecutive daily infusions,...” NCT07577986 ↗2“NKG2D CAR-NK cells (hepatic artery infusion, D0 dose: 1×10⁹ cells,D1 dose: 1×10⁹ cells)” NCT07021534 ↗ |
| Action | Deplete | “NKG2D CAR-NK cells exhibit specific recognition and elimination of such target cells” NCT07577986 ↗ |
| Modality | Cell therapy | “CAR immune cell therapy” NCT07021534 ↗ |
| Route | Other | “NKG2D CAR-NK cells (hepatic artery infusion” NCT07021534 ↗ |